An open-label, single-arm, multi-center phase 2 trial with ofatumumab in patients with relapsed Diffuse Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant

Registry ID

EUCTR2007-004190-26

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

GENMAB

Start date

2008-04-10

Completion date

2014-08-19

Last update

2026-08-16

Conditions

• Linfoma de células B grandes difuso Diffuse Large B-Cell Lymphoma
• Relapsed Diffuse Large B-Cell Lymphoma
• Diffuse Large B-Cell Lymphoma

Summary

To investigate the efficacy of ofatumumab in patients with relapsed DLBCL ineligible for transplant or relapsed after autologous transplant

Locations

• , , Belgium
• , , Denmark
• , , UK
• , , France
• , , Spain
• , , Italy

Related clinical trials

• A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
• A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
• Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
• Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
• Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
• An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

View on source registry